Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: Pharmacokinetics, tolerability, and efficacy

Journal of Acquired Immune Deficiency Syndromes

Volumn 23, Issue 3, 2000, Pages 227-235

  Girard, Pierre Marie ^a   Pegram, Paul Samuel ^b   Diquet, Bertrand ^c   Anderson, Roger ^d   Raffi, François ^e   Tubiana, Roland ^c   Sereni, Daniel ^f   Boerner, Dietmar ^g,h  

^a HÔPITAL ROTHSCHILD   (France)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Anderson Clinical Research   (United States)

^e HÔTEL DIEU   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Clinical trials; Pharmacokinetics; Reverse transcriptase inhibitors

Indexed keywords

FOZIVUDINE TIDOXIL; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VIRUS LOAD;

EID: 0034162182     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200003010-00003     Document Type: Article

References (28)

1. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986;1:575-80.
2. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987;317:192-7.
3. Arts EJ, Wainberg MA. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 1996;40:527-40.
4. Lavie A, Schlichting I, Vetter IR, Konrad M, Reinstein J, Goody RS. The bottleneck in AZT activation. Nat Med 1997;3:922-4.
5. Antonelli G, Turriziani O, Verri A, et al. Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. AIDS Res Hum Retroviruses 1996;12: 223-8.
6. Herrmann DBJ, Kucera LS, Zilch H, Mertens A, Opitz HG. BM 21.1290. In vitro evaluation of a potential new anti-AIDS compound [abstract A.1057]. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, 1996.
7. Herrmann DBJ, Schleger C, Opitz HG. Antiretroviral activity of the novel candidate anti-AIDS drug BM 21-1290 in the friend-virus-leukemia system in vivo [abstract V 160]. Infektionsepidemiol Forsch 1996;47:96.
8. Bogner JR, Boerner D, Muehlhofer A, et al. Single dose, dose-escalating trial with fozivudine tidoxil (BM 21.1290). Antiviral Ther 1997;2:249-56.
9. Bogner JR, Roecken M, Herrmann DBJ, et al. Phase I/II trial with fozivudine tidoxil (BM 21.1290): a 7 day randomized placebocontrolled dose-escalating trial. Antiviral Ther 1997;2:257-64.
10. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333:408-13.
11. Cohen OJ, Pantaleo G, Holodniy M. Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. J Infect Dis 1996;173:849-56.
12. Deeks SG, Collier A, Lalezari J, et al. The safety and efficacy of Adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997;176:1517-23.
13. Saag M, Sonnerborg A, Torres RG, et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS 1998;12:F203-9.
14. Staszewki S, Katlama C, Harrer T, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatmentnaive subjects. AIDS 1998;12:F197-F202.
15. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of patients with mildly symptomatic HIV infection: a double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med 1990;112:727-37.
16. Cooper DA, Pehrson PO, Pedersen C, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind, randomized trial. AIDS 1993;7:197-207.
17. Cooley TP, Kunches LM, Saunders CA, et al. Once-daily administration of 2′,3′+dideoxyinosine (ddl) in patients with me acquired immunodeficiency syndrome or AIDS-related complex. Results of a phase I trial. N Engl J Med 1990;322:1340-5.
18. Diquet B, Simon F, Ory-Lavollee L, et al. Pharmacokinetics of zidovudine and p24 Ag time-course in 48 ARC patients under steady-state conditions. Presented at the V International Conference on AIDS, Montréal, Québec, Canada, 1989.
19. Child S, Montaner J, Tsoukas C, et al. Canadian multicenter azidothymidine trial: AZT pharmacokinetics. J Acquir Immune Defic Syndr 1991;4:865-70.
20. Laskin OL, De Miranda P, Blum MR. Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex. J Infect Dis 1989;159:745-7.
21. Mentre F, Escolano S, Diquet B, Golmard JL, Mallet A. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. Eur J Clin Pharmacol 1993;45:397-407.
22. Drusano GL, Yuen GJ, Lambert JS, Scidilin M, Dolin R, Valentine FT. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. Ann Intern Med 1992;116:562-6.
23. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
24. Zimmerman TP, Mahony WB, Prus KL. 3′-azido-3′-deoxythymidine. An unusual nucleoside analog that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem 1987;262:5748-54.
25. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mono-nuclear cells. J Clin Invest 1993;91:2326-33.
26. Tan CK, Civil R, Mian AM, So AG, Downey KM. Inhibition of Rnase H activity of HIV reverse transcriptase by azidothymidilate. Biochemistry 1991;30:4831-5.
27. Bridges EG, Faraj A, Sommadossi JP. Inhibition of mammalian DNA polymerases-associated 3′ to 5′ exonuclease activity by 5′-monophosphates of 3′-azido-3′-deoxythymidine and 3′-amino-3′-deoxythymidine. Biochem Pharmacol 1993;45:1571-6.
28. Harrington JA, Reardon JE, Spector T. 3′-Azido-3′-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleotide repair of AZT-terminated DNA. Antimicrob Agents Chemother 1993;37:918-20.